Lmb Technologie GmbH Revenue and Competitors
Estimated Revenue & Valuation
- Lmb Technologie GmbH's estimated annual revenue is currently $9.5M per year.
- Lmb Technologie GmbH's estimated revenue per employee is $251,000
Employee Data
- Lmb Technologie GmbH has 38 Employees.
- Lmb Technologie GmbH grew their employee count by 0% last year.
Lmb Technologie GmbH's People
| Name | Title | Email/Phone |
|---|
Lmb Technologie GmbH Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is Lmb Technologie GmbH?
With more than 25 years of experience in the field of blood transfusion, Lmb's offers a comprehensive range of products, including devices for the donation of blood, filtration, separation, irradiation, temperature control, storage and transport of blood components.
keywords:N/A
N/A
Total Funding
38
Number of Employees
$9.5M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Lmb Technologie GmbH News
Fresenius, Haemonetics, Terumo BCT, Delcon, Nigale, Lmb Technologie GmbH, Grfiols, Macopharma, Bioelettrica, Fresenius. This comprehensive Blood Component...
Fresenius, Haemonetics, Terumo BCT, Delcon, Nigale, Lmb Technologie GmbH, Grfiols, Macopharma, Bioelettrica. This comprehensive Blood Component Separator...
... Forecast | Bioelettronica, Infomed, MEDICA, Delcon, Terumo Medical, HAEMONETICS, Grifols, Fresenius Kabi, Lmb Technologie GmbH, Fenwal.
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 38 | 0% | N/A |
#2 | $7.8M | 38 | 6% | $200M |
#3 | $7.4M | 38 | 0% | N/A |
#4 | $7.6M | 38 | -14% | N/A |
#5 | $6.2M | 38 | -39% | N/A |